Mary Ojukwu1, Justice Mbizo2, Bryan Leyva3, Oluwadamilola Olaku4, Farah Zia1. 1. Office of Cancer Complementary and Alternative Medicine, National Cancer Institute, Bethesda, MD, USA. 2. University of West Florida, Pensacola, FL, USA. 3. Process of Care Research Branch, National Cancer Institute, Bethesda, MD, USA. 4. Office of Cancer Complementary and Alternative Medicine, National Cancer Institute, Bethesda, MD, USA Kelly Services Incorporated, Rockville, MD, USA Olakuo@mail.nih.gov.
Abstract
PURPOSE: The purpose of the study was to determine the prevalence of complementary and alternative medicine (CAM) use among US cancer survivors; examine whether use varies by underweight/normal weight, overweight, and obese body mass index status; determine reasons for use; and document disclosure rates of CAM use to medical professionals. METHODS: Data for 1785 cancer survivors were obtained from the 2007 National Health Interview Survey and CAM supplement. The prevalence and associations of CAM use in the previous 12 months were compared among underweight/normal weight, overweight, and obese adult cancer survivors. RESULTS: Nearly 90% of cancer survivors used at least one type of CAM therapy in the 12 months preceding the survey. Those who were overweight, but not obese, were more likely to use a CAM modality compared to normal/underweight respondents. Over two thirds (71%) reported using CAM therapy for general health and wellness and 39.3% used CAM because a health care provider recommended it. Disclosure rates of CAM use to conventional medical professionals varied widely by CAM modality. CONCLUSIONS: An overwhelming majority of US cancer survivors use CAM for a variety of reasons. Overweight cancer survivors may be more likely to use CAM than those who are underweight, normal weight, or obese. Cancer survivors should be screened by medical providers for the use of CAM therapies; furthermore, prospective clinical research evaluating the efficacy and safety of biologically based CAM therapies, often used by cancer survivors, is important and necessary for the well-being of this population.
PURPOSE: The purpose of the study was to determine the prevalence of complementary and alternative medicine (CAM) use among US cancer survivors; examine whether use varies by underweight/normal weight, overweight, and obese body mass index status; determine reasons for use; and document disclosure rates of CAM use to medical professionals. METHODS: Data for 1785 cancer survivors were obtained from the 2007 National Health Interview Survey and CAM supplement. The prevalence and associations of CAM use in the previous 12 months were compared among underweight/normal weight, overweight, and obese adult cancer survivors. RESULTS: Nearly 90% of cancer survivors used at least one type of CAM therapy in the 12 months preceding the survey. Those who were overweight, but not obese, were more likely to use a CAM modality compared to normal/underweight respondents. Over two thirds (71%) reported using CAM therapy for general health and wellness and 39.3% used CAM because a health care provider recommended it. Disclosure rates of CAM use to conventional medical professionals varied widely by CAM modality. CONCLUSIONS: An overwhelming majority of US cancer survivors use CAM for a variety of reasons. Overweight cancer survivors may be more likely to use CAM than those who are underweight, normal weight, or obese. Cancer survivors should be screened by medical providers for the use of CAM therapies; furthermore, prospective clinical research evaluating the efficacy and safety of biologically based CAM therapies, often used by cancer survivors, is important and necessary for the well-being of this population.
Authors: Mallory G Cases; Cindy K Blair; Peter S Hendricks; Kerry Smith; Scott Snyder; Wendy Demark-Wahnefried Journal: BMC Public Health Date: 2022-06-22 Impact factor: 4.135
Authors: Mallory G Cases; Andrew D Frugé; Jennifer F De Los Santos; Julie L Locher; Alan B Cantor; Kerry P Smith; Tony A Glover; Harvey J Cohen; Michael Daniel; Casey D Morrow; Douglas R Moellering; Wendy Demark-Wahnefried Journal: Contemp Clin Trials Date: 2016-08-23 Impact factor: 2.226
Authors: Kerstin A Kessel; Sabrina Lettner; Carmen Kessel; Henning Bier; Tilo Biedermann; Helmut Friess; Peter Herrschbach; Jürgen E Gschwend; Bernhard Meyer; Christian Peschel; Roland Schmid; Markus Schwaiger; Klaus-Dietrich Wolff; Stephanie E Combs Journal: PLoS One Date: 2016-11-03 Impact factor: 3.240